Scarica l'app Stockscreener
67.48
1.03%
0.69
Dopo l'orario di chiusura:
67.48
Precedente Chiudi:
$66.79
Aprire:
$65.99
Volume 24 ore:
1.28M
Relative Volume:
0.98
Capitalizzazione di mercato:
$5.70B
Reddito:
$4.04M
Utile/perdita netta:
$-161.00M
Rapporto P/E:
-32.41
EPS:
-2.0823
Flusso di cassa netto:
$-132.48M
1 W Prestazione:
+1.21%
1M Prestazione:
+16.83%
6M Prestazione:
+69.31%
1 anno Prestazione:
+203.42%
Intervallo 1D:
$65.97
$68.40
Intervallo di 1 settimana:
$63.14
$69.30
Portata 52W:
$14.80
$69.35
Cg Oncology Inc Stock (CGON) Company Profile
Nome
Cg Oncology Inc
Settore
Industria
Telefono
(949) 419-6203
Indirizzo
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
67.48 | 5.70B | 4.04M | -161.00M | -132.48M | -2.0823 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-11 | Iniziato | Wedbush | Outperform |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-10-08 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-05-02 | Iniziato | JP Morgan | Overweight |
| 2025-04-16 | Iniziato | Scotiabank | Sector Perform |
| 2025-01-07 | Iniziato | TD Cowen | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2024-06-28 | Iniziato | BofA Securities | Buy |
| 2024-02-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-02-20 | Iniziato | Goldman | Neutral |
| 2024-02-20 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-14 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cg Oncology Inc Borsa (CGON) Ultime notizie
CG Oncology: Passing A Red Line For What I Would Call A Reasonable Valuation (Rating Downgrade) - seekingalpha.com
CG Oncology stock hits all-time high at 60.01 USD By Investing.com - au.investing.com
CG Oncology Stock Surges on Fresh Institutional Backing - TipRanks
CGON PE Ratio & Valuation, Is CGON Overvalued - intellectia.ai
Aug Action: What is the target price for CG Oncology Inc stock2026 EndofYear Setup & Consistent Return Strategy Ideas - baoquankhu1.vn
Trade Recap: Can CG Oncology Inc expand into new markets - baoquankhu1.vn
Portfolio Recap: Is CG Oncology Inc impacted by rising ratesMarket Weekly Review & Expert Approved Momentum Ideas - baoquankhu1.vn
CG Oncology, Inc. $CGON Stake Lifted by JPMorgan Chase & Co. - MarketBeat
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know - AOL.com
Analysts Are Bullish on These Healthcare Stocks: Gain Therapeutics (GANX), CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology (NASDAQ:CGON) Downgraded by Wall Street Zen to Sell - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON): Are Analysts Optimistic? - 富途牛牛
Vanguard realignment reports 0% ownership in CG Oncology (CGON) - Stock Titan
UBS raises CG Oncology stock price target to $90 on trial outlook - Investing.com India
UBS Adjusts Price Target on CG Oncology to $90 From $60, Maintains Buy Rating - MarketScreener
UBS raises CG Oncology stock price target to $90 on trial outlook By Investing.com - za.investing.com
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ - openPR.com
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - Barchart.com
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale - AOL.com
Kynam Capital Cuts CG Oncology Holding: Q4 2025 Sale Details & ImpactNews and Statistics - IndexBox
This Biotech Stock Surged 135% but Just Saw a $44 Million Sell-Off. What Does This Mean for Investors? - Bitget
CGON Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bank of America Securities Remains a Buy on CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology (CGON) Expected to Announce Quarterly Earnings on Friday - MarketBeat
Quarterly Trades: Can CG Oncology Inc deliver consistent EPS growth2026 Key Highlights & Real-Time Price Movement Reports - baoquankhu1.vn
Why CG Oncology Stock Is Suddenly Losing Steam - TipRanks
CG Oncology, Inc. Hits New 52-Week High of $59.95 - Markets Mojo
Highs Report: What is the dividend yield of CG Oncology IncWeekly Trade Review & Expert Verified Movement Alerts - baoquankhu1.vn
Dividend Watch: Is CG Oncology Inc impacted by rising rates2026 Earnings Surprises & Community Trade Idea Sharing - baoquankhu1.vn
Will CG Oncology Inc outperform tech stocksEarnings Miss & Growth Oriented Trade Recommendations - baoquankhu1.vn
CG Oncology (NASDAQ:CGON) Director James Mulay Sells 1,964 Shares - MarketBeat
CG Oncology (NASDAQ: CGON) director sells 1,964 shares after option exercises - Stock Titan
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Protagonist Therapeutics (PTGX) and CG Oncology, Inc. (CGON) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology, Inc. $CGON Stake Increased by HighVista Strategies LLC - MarketBeat
Boothbay Fund Management LLC Has $3.81 Million Stock Holdings in CG Oncology, Inc. $CGON - MarketBeat
CG Oncology, Inc. $CGON Stake Lessened by Cinctive Capital Management LP - MarketBeat
CG Oncology (NASDAQ:CGON) Reaches New 52-Week HighShould You Buy? - MarketBeat
ArrowMark Colorado Holdings LLC Has $10.36 Million Holdings in CG Oncology, Inc. $CGON - MarketBeat
How Investors May Respond To CG Oncology (CGON) Expanding ATM Offering To Advance Cretostimogene BLA Efforts - simplywall.st
CG Oncology stock hits all-time high at 63.9 USD By Investing.com - Investing.com Nigeria
Is CG Oncology (CGON) Pricing Reflect Its Recent 131% Surge And Cancer Breakthrough Hopes - Yahoo Finance
Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade - MSN
Mangrove Partners IM LLC Increases Stock Position in CG Oncology, Inc. $CGON - MarketBeat
Form 4 CG Oncology Inc For: 14 March - Investing.com
CG Oncology (NASDAQ: CGON) CEO net exercises options and increases share stake - Stock Titan
Rosalind Advisors Inc. Grows Holdings in CG Oncology, Inc. $CGON - MarketBeat
Is It Too Late To Consider CG Oncology (CGON) After A 143% One Year Surge? - simplywall.st
CG Oncology stock rallies nearly 32% in a week: Here is why - MSN
Cg Oncology Inc Azioni (CGON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):